# Paul DiSilvestro

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/paul-disilvestro/

## Facts

| Field | Value |
| --- | --- |
| Citations | 15,970 |
| Field | Ovarian cancer diagnosis and treatment |
| h-index | 47 |
| i10-index | 114 |
| Last Known Institution | Providence College |
| OpenAlex ID | https://openalex.org/A5033923828 |
| ORCID iD | 0000-0003-2711-6663 |
| Works | 271 |

## Researcher papers

- [Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer](https://scholariq.org/papers/maintenance-olaparib-in-patients-with-newly-diagnosed-advanced-ovarian-cancer/)
- [Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer](https://scholariq.org/papers/veliparib-with-first-line-chemotherapy-and-as-maintenance-therapy-in-ovarian/)
- [A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass](https://scholariq.org/papers/a-novel-multiple-marker-bioassay-utilizing-he4-and-ca125-for-the-prediction-of/)
- [Inherited Mutations in Women With Ovarian Carcinoma](https://scholariq.org/papers/inherited-mutations-in-women-with-ovarian-carcinoma/)
- [The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass](https://scholariq.org/papers/the-use-of-multiple-novel-tumor-biomarkers-for-the-detection-of-ovarian/)
- [Bevacizumab and paclitaxel–carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial](https://scholariq.org/papers/bevacizumab-and-paclitaxel-carboplatin-chemotherapy-and-secondary-cytoreduction/)
- [Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial](https://scholariq.org/papers/niraparib-monotherapy-for-late-line-treatment-of-ovarian-cancer-quadra-a/)
- [Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial](https://scholariq.org/papers/overall-survival-with-maintenance-olaparib-at-a-7-year-follow-up-in-patients/)
- [Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial Cancer](https://scholariq.org/papers/adjuvant-chemotherapy-plus-radiation-for-locally-advanced-endometrial-cancer/)
- [Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer](https://scholariq.org/papers/weekly-vs-every-3-week-paclitaxel-and-carboplatin-for-ovarian-cancer/)
- [Health-related quality of life in patients with newly diagnosed advanced ovarian cancer treated with niraparib vs placebo: Results from the phase 3 randomized PRIMA/ENGOT-OV26/GOG-3012 trial](https://scholariq.org/papers/health-related-quality-of-life-in-patients-with-newly-diagnosed-advanced-ovarian/)

## Researcher topics

- [Ovarian cancer diagnosis and treatment](https://scholariq.org/topics/ovarian-cancer-diagnosis-and-treatment/)
- [Endometrial and Cervical Cancer Treatments](https://scholariq.org/topics/endometrial-and-cervical-cancer-treatments/)
- [PARP inhibition in cancer therapy](https://scholariq.org/topics/parp-inhibition-in-cancer-therapy/)
- [BRCA gene mutations in cancer](https://scholariq.org/topics/brca-gene-mutations-in-cancer/)
- [Cervical Cancer and HPV Research](https://scholariq.org/topics/cervical-cancer-and-hpv-research/)

## Researcher university

- [Providence College](https://scholariq.org/institutions/providence-college/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.